Sun Pharma gets FDA approval to mkt Octreotide injection

RELATED NEWS Buy Sun Pharma; target Rs 1287: Share khan Research Sun Pharma to raise Rs 35bn for generic acquisitions Sun Pharma Q1 net seen up 34% at Rs 218.76cr Nicholas Piramal to divest stake in R&D biz ALSO READ See latest News about Novartis India See previous management interviews See what other Experts & Brokerages are saying about Novartis India Novartis India BSE | NSE 01/01/70 Are Mutual Funds betting on Novartis India? Other Stocks in this news Sun Pharmaceutical Industries |

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the Company's multiple Abbreviated New Drug Applications (ANDAs) for Octreotide acetate injection in vials and ampoules.

 

Octreotide acetate is indicated to reduce blood levels of growth hormone and IGF-I in acromegaly patients who have inadequate response or cannot be treated with other methods. It is also indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Yet another use is the treatment of profuse watery diarrhea associated with VIP secreting tumors.

 

These generic octreotide injections are bioequivalent to Sandostatin®, a registered trademark of Novartis and will be available in 5 ml multiple-dose vials (0.2 mg/ ml and 1 mg/ml) and 1 ml single-use ampoules (0.05 mg (base)/ml, 0.1mg (base)/ml, 0.5mg (base)/ml). These strengths of octreotide generic and branded products had annual sales of approximately USD 100 million in the US.

 

This is the second injectable approval from the plant in Halol, India. The Company expects to reach the market shortly with these products. 

 

Sourced From: Sun Pharmaceutical Industries Ltd